Fig. 1

MSC-ex homing to the fibrotic liver and inhibited LOXL2 expression. A TEM image of MSC-ex and schematic illustration of in vivo experiments. Briefly, mice were administered with MSC-ex (50 μg or 100 μg), BAPN, or PBS at 6 weeks to 10 weeks on CCl4-induced liver fibrosis (n = 6). Scale bars, 100 nm. B Nanoparticle tracking analysis of MSC-ex. C Western blot analysis of exosomal markers CD9, CD63, Tsg101, and ER membrane marker Calnexin in MSC-ex. D Imaging of fluorescence intensity in mice from PBS or DiR labeled MSC-ex group at 24 h post-treatment. Scale bars, 1.0 cm. E qRT-PCR analysis for LOXL2 and Col1A2 mRNA in livers from PBS, MSC-ex, or BAPN-treated mice (n = 6; ***p < .001). F ELISA analysis for serum LOXL2 in PBS, MSC-ex, or BAPN-treated mice (n = 6; **p < .01, ***p < .001). G Immunohistochemistry staining for LOXL2 and Col1A2 in mouse livers. Scale bars, 100 μm. H Western blot analysis and quantification for LOXL2 and Col1A2 protein in mouse livers (n = 3; **p < .01). I Sirus Red staining of collagen deposition in mouse livers. The collagen area of fibrotic livers was quantified (n = 6; ***p < .001). Scale bars, 100 μm